Reading study results - D:A:D study - BHIVA treatment guidelines - GSK
Training and presentations: Interpreting risk and confidence in study results - D:A:D study: abacavir, ddI and risk of heart attack - conference feedback from CROI 2008.
Company meeting: GlaxoSmithKline - abacavir and data on risk of heart attack, drugs in development.
Community consultation: BHIVA draft treatment guidelines.
Training and presentations: BHIVA 2007 clinical audit: treatment of naïve patients - campaigning for microbicides - promoting PEPSE: role of the HIV treatment advocate - PrEP (pre-exposure prophylaxis).
Company meeting: Pfizer - the drug development process.
Access to treatment for migrants and people facing deportation - Roche
Training and presentations: Access to treatment for migrants and people facing deportation: the clinician's perspective
- HIV in removal centres - feedback from European AIDS Clinical Society Conference 2007, Madrid
Company meeting: Roche - nelfinavir recall, GEMINI study, Biojector.
Training and presentations: Rapid testing in practice - testing: the standard of care and some other useful tests - viral tropism - monitoring HIV infection and treatment in the 2nd decade of HAART - feedback from AIDS Impact Conference - Yellow Card scheme.
Training and presentations: UK HIV drug resistance database - genetics and higher NNRTI levels in Africans - African treatment issues: response to treatment, side effects, treatment access and other issues - feedback from CROI 2007: new pipeline drugs.
Company meeting: Merck - raltegravir and integrase inhibitors.
Training and presentations: HIV related brain impairment - feedback from World Haemophilia Congress 2006, Vancouver, AIDS 2006, Toronto and meetings on HIV transmission and criminalisation.
Treatment access in eastern Europe - hepatitis C coinfection - Pfizer
Training and presentations:Treatment access in eastern Europe - hepatitis C coinfection - feedback from BHIVA conference, European AIDS Clinical Society Conference 2005, Dublin and International Workshop on Adverse Drug Reactions and Lipodystrophy 2005, Dublin - Global Fund.
Community participation in preventive HIV vaccine trials
Training and presentations:: Approaches to community participation in preventive HIV vaccine trials - feedback from International Congress on HIV and Drug Therapy 2004, Glasgow.
Introduction to statistics 3 - AIDS 2004 conference
Training and presentations: Introduction to statistics session 5-6 - feedback from AIDS 2004, Bangkok: mother-to-child transmission, harm reduction and IDUs, 3TC monotherapy, Kaletra monotherapy, pharmacology and drug interactions, treatment access.
Training and presentations: Introduction to basic vaccine technology - topical microbicides - Internationl AIDS Vaccine Initiative (IAVI) - Community involvement in vaccine and microbicide research - thorny issues in HIV vaccine research - feedback from BHIVA conference.
Training and presentations: Introduction to statistics sessions 3-4 - hepatitis C coinfection: APRICOT study - feedback from CROI 2004: mother to child transmission, women, hepatitis C coinfection.
Company meeting: BMS - Atazanavir: update, access and pricing in UK.
Training and presentations: New data from new data from 2nd IAS conference, Paris: Trizivir, emtricitabine, nuke-sparing combinations, atazanavir and boosted PI regimens T20, new formulations of nelfinavir and saquinavir, SIMBA study (reducing mother-to-baby transmission and breast-feeding) - feedback from lipodystrophy and resistance workshops.
Company meeting: GlaxoSmithKline - ACTG 5095 study, abacavir and tenofovir interaction, fosamprenavir, neuropathy, viral fitness.
Women and HIV - HIV, coinfections and multiple conditions - Roche
Training and presentations: Women and HIV: why gender is a real issue - hepatitis C coinfection - living with multiple conditions - 48 weeks of interferon and ribavirin: was it worth it?
Company meeting: Roche - Hepatitis C products: trial results, side effects, pricing and access, future developments.
HIV, pregnancy and maternal heath - Boehringer Ingelheim
Training and presentations: Of mothers, orphans and the HIV pandemic - Principles of care of the HIV-1 infected pregnant mother - Fertility treatment and spermashing.
Company meeting: Boehringer Ingelheim - Tipranavir: trials, resistance and clinical data, nevirapine use in pregnancy, drugs in development: hepatitis C protease inhibitor.
Training and presentations: Basic mechanisms of resistance: how to avoid resistance, when to change treatment, how to interpret different resistance tests - approaches to salvage therapy: avoiding initial failure, mega-HAART including OPTIMA study, treatment interruptions, use of new drugs.
Company meeting: BMS - Atazanavir: overview, resistance, safety, side effects, lipids and expanded access programme, ddI interaction with tenofovir, d4T XR, BMS-561390 (DPC-083).
Training and presentations: Clinical trials: structure, timelines, design, .basic statistics and study power - informed consent and patient involvement in trial - role of advocates - UK, European and US CABs (Community Advisory Boards).
Company meeting: Gilead - tenofovir, adefovir for hepatitis B, cidofovir
